AAAAAA

   
Results: 1-2 |
Results: 2
Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide
Authors: Kuhn, JM Arlot, S Lefebvre, H Caron, P Cortet-Rudelli, C Archambaud, F Chanson, P Tabarin, A Goth, MI Blumberg, J Catus, F Ispas, S Beck-Peccoz, P
Citation: Jm. Kuhn et al., Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide, J CLIN END, 85(4), 2000, pp. 1487-1491
Treatment of carcinoid syndrome - A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, andtolerance
Authors: O'Toole, D Ducreux, M Bommelaer, G Wemeau, JL Bouche, O Catus, F Blumberg, J Ruszniewski, P
Citation: D. O'Toole et al., Treatment of carcinoid syndrome - A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, andtolerance, CANCER, 88(4), 2000, pp. 770-776
Risultati: 1-2 |